AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05963490 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: hypofractionated radiotherapy (5 fractions of 4-12Gy) and low-dose radiotherapy (5 fractions of 0.5-2Gy).
Study NCT05963490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Regorafenib 80mg orally once daily on days 1-21 of each 28 days cycle.
Study NCT05336812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Given PO
Study NCT04699890 — intervention group
Intervention type: OTHER
Intervention: Blood sampling, questionnaires and specific exams
Description: Patients will have additionnal blood samples, answer to self-questionnaires and will performed an electrocardiogram and an echocardiography if not performed in routine care.
Study NCT05336812 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Given IV
Study NCT05336812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study NCT06056310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xevinapant
Description: Participants will receive xevinapant once daily from Day 1 to Day 14, per 3-week cycle (Each cycle is of 3 weeks). The first three cycles are given in combination with weekly cisplatin and radiotherapy, followed by 3 cycles of monotherapy xevinapant.
Study NCT06056310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Participants will receive weekly cisplatin for 7 weeks on Cycle 1 Day 2 (C1D2), C1D9, C1D16, C2D2, C2D9, C2D16, and C3D2).
Study NCT06056310 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy (IMRT)
Description: Participants will receive 70 Gray (Gy) of IMRT in 35 fractions, 2 Gy/fraction, 5 days/week
Study NCT04580238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox 200 UNT Injection
Description: Treatment Protocol:~Botox 200 IU vials for 40 patients for the duration of study (4 treatment cycles); Treatment will be based on the PREEMPT study full treatment (standard of care) and follow the pain protocol to a total of 195 IU in standard injection sites
Study NCT04580238 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Non Botox based Standard of Care Treatments for Headache/Migraine
Description: Control Group will receive normal standard of care Non-Botox based interventions.
Study NCT06521710 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraoperative Somatic-Autonomic Nerve Grafting
Description: A one-sided graft using a genitofemoral (GFN) nerve graft between one obturator nerve and the corpora cavernosa
Study NCT05528055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCR-6920 capsule
Description: SCR-6920 capsule will be oral administered once daily at escalating doses on a continuous basis
Study NCT05528055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCR-6920 capsule
Description: SCR-6920 capsule will be oral administered once daily at the recommended phase 2 dose on a continuous basis
Study NCT05383209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EYP-1901
Description: Intravitreal Injection
Study NCT05383209 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham IVT
Description: Sham IVT
Study NCT04862065 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Alinity s Anti-HCV II
Description: For all donor specimens with investigational Alinity s Anti-HCV II results that are discordant with final status after supplemental testing, an attempt will be made to obtain a follow-up whole blood specimen approximately 4 to 6 weeks after initial donation for further analysis.
Study NCT06468098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI363 + chemotherapy
Description: In this group, patients will receive IBI363 and chemotherapy
Study NCT06468098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI363 + Investigator's Choice SOC
Description: In this group, patients will receive IBI363 and Investigator's Choice SOC
Study NCT05768100 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 1,3-Butanediol
Description: 1,3-Butanediol
Study NCT05768100 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Isovolumic placebo
Study NCT05299398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trazodone
Description: Trazodone capsule once daily
Study NCT05299398 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule once daily
Study NCT05313789 — intervention group
Intervention type: DEVICE
Intervention: Analgesia Nociception Index (ANI)
Description: Monitorization of Analgesia Nociception Index in Intensive Care Patients
Study NCT05936489 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Aceclidine + Brimonidine
Description: LNZ101 (Aceclidine/Brimonidine) non-preserved ophthalmic solution
Study NCT05936489 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Aceclidine
Description: LNZ100 (Aceclidine) non-preserved ophthalmic solution
Study NCT04692623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400mg
Description: Blood will be checked for glucose levels and ECG at Baseline(Day Ist) and at Steady state Steady state(Tmax) via Glucometer and ECG machine will be used for determination of serum insulin levels.
Study NCT04692623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemifloxacin 320 MG
Description: Blood will be checked for glucose levels and ECG at Baseline(Day Ist) and at Steady state(Tmax) via Glucometer and ECG machine will be used for determination of serum insulin levels.
Study NCT06349694 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous MPN stimulation (T-MPNS)
Description: Transcutaneous MPN stimulation (T-MPNS) is the electrostimulation of the lumbosacral roots that produce an activation of the lumbosacral plexus that controls the visceral organs and the pelvic floor muscles, thereby improving bladder control.
Study NCT06349694 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous tibial nerve stimulation (TTNS)
Description: Transcutaneous tibial nerve stimulation (TTNS) is the electrostimulation of the lumbosacral roots that produce an activation of the lumbosacral plexus that controls the visceral organs and the pelvic floor muscles, thereby improving bladder control.
Study NCT06349694 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BT (Control group)
Description: Conventional bladder training
Study NCT06457724 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Levilactobacillus brevis CNCM I-5566
Description: Participants will take four Mucomixx tablets (containing Levilactobacillus brevis CNCM I-5566) daily for 28 days. The tablets should be taken after each of the following meals: breakfast, lunch, afternoon break, and dinner.
Study NCT06457724 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will take four placebo tablets daily for 28 days. The tablets should be taken after each of the following meals: breakfast, lunch, afternoon break, and dinner.
Study NCT05260268 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TEST Intervention
Description: The TEST intervention will include standard post-transplant care and include additional touchpoints utilizing the Way to Health system. Details on this intervention are included in the study arm description.
Study NCT05034913 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital photography measurements
Description: The participant will be instructed to take off any thick outer layers and leave on shirt and pants. Tops will be gathered to make cloth tight to body. The participant will stand next to an 8 ½ x 11 piece of paper taped to a wall, to use as a reference for linear regression calculations.
Study NCT05794035 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surgery with additional moderate hypofractionation RT (15 fractions)
Description: After randomization, patients will then be followed-up at 3 months post randomization and at each surveillance visit (M6, M12, M24 and M36).~Adjuvant Radiotherapy:~-Arm B: Surgery followed by moderate hypofractionation RT (15 fractions): 45Gy in 15 fractions, 3 fractions per week over 5 weeks to the operative bed.
Study NCT05794035 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Surgery alone, without radiation post surgery
Description: Arm A: Surgery alone followed by surveillance
Study NCT05794035 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Surgery with extreme hypo fractionation treatment (HF)
Description: After randomization, patients will then be followed-up at 3 months post randomization and at each surveillance visit (M6, M12, M24 and M36).~Adjuvant Radiotherapy:~-Arm C= Surgery followed by extreme hypofractionation RT (5 fractions, 2 fractions/week): 30Gy in 5 fractions of 6Gy over 5 weeks to the operative bed.
Study NCT05280717 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sotrovimab
Description: via IM injection
Study NCT05280717 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sotrovimab
Description: via IV injection
Study NCT05280717 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sotrovimab
Description: via IV infusion
Study NCT05691881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-NY105
Description: Patients will receive a tracer (20-40mcg, IV) dose of 68Ga (2-5mCi) labelled NY105
Study NCT06125704 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Moderate intensity walking or stepping
Description: 30 minutes of moderate intensity walking or stepping (i.e., at a pace of approximately 100 steps per minute), varied by time of day it is performed: morning (i.e., between 5am-9am, within 30-40 minutes of starting breakfast) versus late afternoon/evening (i.e., between 4pm-8pm, within 30-40 minutes of dinner).
Study NCT05961267 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: A gynecological follow-up questionnaire will be proposed to patients with one of the above mentioned pathologies. This is a standardized questionnaire specifically designed for this study.
Study NCT05395000 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Videos
Description: A short video explaining briefly what type 1 diabetes is, the symptoms of hypoglycemia and the usefulness of glucagon as well as two short videos explaining how to administer glucagon, all less than 3 minutes long, will be viewed by the 2 groups for intranasal glucagon and injectable glucagon. Participants will have access to the videos for 2 weeks, approximately 3 months before the next stages of the project.
Study NCT05395000 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simulation
Description: An intranasal and injectable glucagon administration test on a mannequin in a simulated stress environment will be done.
Study NCT05395000 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interview
Description: At the end of the simulation, participants will participate in a semi-structured, recorded individual interview of approximately 20 minutes to share their experience related to preferences, barriers, emotional impact, and method of teaching the use of the two glucagon formulations.
Study NCT06344338 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS stimulation
Description: In the real-stimulation group, Treatment was for 20 min, repeated twice in a day, then again over the next few days. The maximum number of stimuli required to terminate the status epilepticus should not exceed 10. In the sham-stimulation group, The duration and frequency of tDCS are the same as those in the treatment group, but the tDCS device is not active during the 20 minutes of sham-stimulation
Study NCT06344338 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TDCS sham-stimulation
Description: TDCS sham-stimulation
Study NCT06159062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 162
Description: The investigational product 162 is a novel monoclonal antibody targeting HBsAg.
Study NCT06159062 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo do not consist any active ingredients.
Study NCT04309110 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: or geko™ X-T3
Description: The geko™ X-T3 is a next generation self adhesive medical device incorporating a new formulation skin adhesive. It is about the size of a wrist watch which attaches to the side of the knee and when switched on, gentle painless electrical pulses are produced which contract the calf muscles and increase blood flow to the lower leg. The only difference between the currently used geko™ T3 device and the new geko™ XT-3 device is the adhesive used to attach each device to the skin.
Study NCT05661344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1015550
Description: BI 1015550
Study NCT05107544 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIGH INTENSITY INTERVAL TRAINING
Description: Will be prescribed HIIT through online modality to a group of adolescents with type 1 diabetes 3 times a week for 3 months. The training is going to have 2 phases, the initial phase and improvement phase, which are going to be differentiated according to work intensity following the recommendations of the American College of Sports Medicine. During the initial phase (first 4 weeks) the intensity is going to be 60-75% of the VO2 max. During the improvement phase the intensity is going to increase to a 75-85% of the VO2 max for 8 week.
Study NCT06555185 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Potentiation warm-up protocol
Description: The intervention protocol consisted of i) 1st set - six hurdle jumps, with a distance of 70 cm between each, followed by a 15-m sprint with COD; (ii) 2nd set - six lateral hurdle jumps (three to the left and three to the right) followed by a 10-m sprint with COD; (iii) 3rd set - six bouncy strides, followed by a 15-m sprint with COD; (iv) 4th set - six broad jumps followed by a 10-m sprint with COD. All COD circuits had different configurations, changing the sprint distance and the angle of the COD curve. All repetitions and sets were separated by 90-second recovery intervals, and each set was performed three times.
Study NCT06555185 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual warm-up protocol
Description: The usual warm-up consisted of (i) The first phase included dynamic stretching and drills to increase body temperature. This phase lasted 5-min and included slow jogging, light skipping, and dynamic stretches for hip flexors, glutes, quads, hamstrings, abductors, gastrocnemius and lower limb joints. (ii) The second phase was composed of exercises that intended to mimic specific movements of the football match, both with and without ball possession. This phase lasted 15 minutes and included exercises with and without possession of the ball, such as acceleration, COD, jumping over hurdles, and playful games with ball possession. In this group, the players only rested in a slow jog when they moved from the first to the second phase.
Study NCT06199934 — intervention group
Intervention type: BIOLOGICAL
Intervention: Vaccination
Description: BNT162b2 vaccination
Study NCT06085534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNK01001
Description: Capsules for oral use
Study NCT06085534 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LNK01001
Description: Capsules for oral use
Study NCT06085534 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules for oral use
Study NCT04418778 — intervention group
Intervention type: BEHAVIORAL
Intervention: BEAR
Description: Building Empowerment and Resilience Therapy group
Study NCT05123534 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: SONALA-001 (ALA) and MR-Guided Focused Ultrasound device (MRgFUS)
Description: SONALA-001(ALA) given 6-12 hours prior to receiving the MRgFUS.
Study NCT05648266 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continous SAPB (Ropivacain)
Description: postoperative SAPB and pain catheter with continous administered (5ml/h Ropivacain 0,2%) for 48h
Study NCT05648266 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: institutional standard of care pain medication protocol
Description: institutional standard of care pain medication protocol
Study NCT05648266 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: institutional standard of care pain medication protocol
Description: institutional standard of care pain medication protocol
Study NCT06360146 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early mobilisation
Description: Breathing exercises, inspiratory muscle strength, postural drainage, functional exercise (stand up and sitting down on the chair, walking inward, back-ward ,and sideways), weight shifts from left to right, step up inside the patch , one leg stand, squatting leaning against wall) for three times per the day and repetition fifteen times (3 times per day for 15 repetition) and supervised walking with increments of 2 minutes, as tolerated up to 6 minutes or more at the morning, afternoon, evening and at night.
Study NCT06360146 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Early mobilisation
Description: Breathing exercises, inspiratory muscle strength, postural drainage, functional exercise (stand up and sitting down on the chair, walking inward, back-ward ,and sideways), weight shifts from left to right, step up inside the patch , one leg stand, squatting leaning against wall) for three times per the day and repetition fifteen times (3 times per day for 15 repetition) and supervised walking with increments of 2 minutes, as tolerated up to 6 minutes or more at the morning, afternoon, evening and at night.
Study NCT06314334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab+Pegaspargase
Description: 1. Sintilimab, 200mg intravenous drip, on day 1;~2. pegaspargase, 2000U/m\^2, capped at 3750U, intramuscular, day 1;
Study NCT06314334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P-GemOx
Description: 1. pegaspargase 2000U/m\^2, capped at 3750U on day 1, intramuscular;~2. gemcitabine 1.0g/m\^2 on day 1 and day 8, intravenous drip;~3. oxaliplatin 130mg/m\^2 on day 1, intravenous drip
Study NCT06314334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GELAD
Description: 1. gemcitabine 1.0g/m\^2 on day 1, intravenous drip;~2. etoposide 60mg/m\^2 on day 1-3, intravenous drip;~3. pegaspargase 2000U/m\^2, capped at 3750U on day 1,intramuscular;~4. dexamethasone 20mg on day 1-4, intravenous drip.
Study NCT06314334 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: Intensity modulated radiotherapy (50-56Gy)
Study NCT06256172 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medlink
Description: The 10 Patients enrolled in this arm tested the ue of Medlink in Measuring and reporting their Physiological Paramters in Oder to remotely obtain access to health care for the following diseases: Myasthenia Gravis, Hypertension, Chronic Heart Failure, Diabetes Mellitus, and Chronic Obstruction Pulmonary Disorder.
Study NCT05305352 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Very low carbohydrate dietary intervention
Description: The experimental group will be counseled about very low carbohydrate diet i.e., \<10% carbohydrate,40-50% protein and lipid in diet).
Study NCT05973734 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infusion of recipient T regulatory cell
Description: Patients will undergo a single apheresis collection with a target total blood volume of 20-30 L and the collected cells used as the source of purified Tregs to be infused following the islet transplantation. In the event a patient is unable to meet the collection target, a second collection may be performed.
Study NCT05973734 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infusion of concomitant Donor Derived Vertebral Bone Marrow
Description: The cells from the donor VB and spleen are processed under cGMP conditions and released for infusion after the respective recipient has undergone transplant and conditioning. Under this protocol, the donor's VB will be obtained at the same time as the pancreatic islets and will be the source of HSC for infusion with the intent to establish immune tolerance to the donor's pancreatic islet cells. Subjects will receive one infusion of allogeneic cadaveric islets. Subjects will receive induction therapy with ATG and Belatacept and maintenance immunosuppression with Tacrolimus Extended-release tablets (Envarsus XR) and Mycophenolate Mofetil (MMF). After islet transplantation, the VBM cells will be infused in one time window: on day 0-1. Subjects will undergo closed-loop insulin pump glucose control peri-transplant.
Study NCT05695807 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carboxytherapy
Description: Device generating CO2 gas
Study NCT05695807 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Carboxytherapy
Description: Device generating CO2 gas
Study NCT05860088 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beef Diet
Description: Controlled-Feeding Diet Intervention
Study NCT05860088 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vegetarian Diet
Description: Controlled-Feeding Diet Intervention
Study NCT05821699 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LCS (Life Care Specialist)
Description: The LCS will work with the patient to create a pain management plan focused on behavioral education. The LCS interventions can encompass all, but not limited to, the information included below:~* Opioid Risk Education~* Therapeutic Intervention~* Clinical Pain Coordination